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Comment on: parotid gland biopsy compared with labial
biopsy in the diagnosis of patients with primary Sjogren’s
Syndrome
SIR, We read with interest the report of Pijpe et al. [1] comparing
parotid gland with labial biopsy in 35 patients with Sjogren’s
Syndrome (SS).
We agree with the authors about the difficulties arising from the
use of labial gland biopsy in the diagnosis of SS, particularly related
to the histological evaluation of focus score (FS), requiring skilled
pathologists. Although Greenspan and Daniels standardized the
methodology in assessing FS [2] and many authors evidenced
its importance in the diagnostic evaluation [3, 4], its reproducibility
at different section levels within the same sample seems to be low,
probably because of the unhomogeneous distribution of the
inflammatory infiltrates in the gland and of the sample’s size [5].
To overcome this problem, in a recently published study [6], we
proposed the application of a multi-level analysis of labial gland
specimens to maximize the number of foci, the glandular area and
the technical quality of the material. We studied 120 labial gland
biopsies from patients with suspected SS; less-than-optimal area
(<4mm2) specimens were not excluded provided that at least one
normotrophic glandular lobule was present. After evaluation of
the FS according to Greenspan and Daniels, the slides were recut
at 200m intervals from each. A cumulative focus score (cFS) on
three slides for each sample was analysed. Patients were evaluated
by clinicians blind to the re-evaluation and classified has having
or not SS according to the American–European consensus group
(AECG) criteria set [3]. The cFS was then substituted to the
baseline FS in the criteria set. Statistical analysis using receiver
operating characteristic curve evidenced that the diagnostic
performance of the AECG criteria significantly improved, when
cFS was entered in the criteria set: the specificity was increased
by 9.8% without affecting sensitivity. The improvement
was mostly due to the increased specificity in biopsies with FS
between 1 and 2, historically the most critical cut-off. Moreover,
this method allowed the evaluation of smaller samples of labial
glands. In our opinion, it should be of great interest to compare
multi-level analysis of labial biopsies with parotid biopsy.
The second point we would like to address is related to the
morbidity of labial biopsies. We read the comment by Friedman
and colleagues [7] and we found many analogies with our personal
experience. From August 1998, we performed 502 consecutive
minor salivary gland biopsies (MSGB) as part of an evaluation
for suspected SS or other oral infiltrative diseases (such as
amyloidosis). All patients gave their informed consent for surgical
procedures according to the local Ethical Committee recommenda-
tions. All MSGBs have been performed by two rheumatologists of
our Operative Unit adopting a simple technique similar to that
described by Friedman [8]. In our experience, a small incision
(2–3mm) was sufficient for collecting glands. Adverse events were
recorded by an independent clinician immediately and 7 days,
14 days and 6 months after the procedure with the aid of a
questionary. The procedure was well tolerated in all cases: nomajor
adverse events were observed, 12.7% of patients complaint
transient adverse events lasting less than 14 days. Only one patient
(0.2%) still complains local paresthesia after 2 years. Owing to the
fact that such scarcely-invasive technique might provide insuffi-
cient material for the histological evaluation for SS, we extensively
adopted the multi-level examination. We observed that, due to
the application of the cFS, only 1% of samples did not provide
adequate material and the percentage of false-positive biopsies was
lower (1.6%) than reported by Pijpe and colleagues [1].
In our opinion, these data confirm the need for further large
comparative studies, in order to find out the best diagnostic tools
for histopathological evaluation of SS, taking in mind that while
parotid gland biopsy requires specific surgical experience, MSGB
may be performed directly by rheumatologists [1].
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Comment on: parotid gland biopsy compared with labial
biopsy in the diagnosis of patients with primary Sjogren’s
Syndrome: reply
SIR,
We would like to thank Dr. Morbini and co-workers for their
valuable remarks on our study comparing parotid gland with
labial biopsy in Sjo¨gren’s syndrome (SS) [1]. Morbini and co-
workers addressed an important topic regarding the validity of
salivary gland biopsies in the diagnosis of SS. In their well
performed study regarding multilevel examination of labial gland
biopsy specimens in the diagnosis of SS, they showed that the
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